Amgen, Inc. (AMGN) Misses Q4 EPS by 1c; Guides FY12 EPS
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $397.51 -9.08%
Revenue Growth %: +5.1%
Financial Fact:
Net income: 2.02B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.1%
Financial Fact:
Net income: 2.02B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amgen, Inc. (NASDAQ: AMGN) reported Q4 EPS of $1.21, $0.01 worse than the analyst estimate of $1.22. Revenue for the quarter came in at $3.97 billion versus the consensus estimate of $3.91 billion.
Amgen, Inc. sees FY2012 EPS of $5.90-$6.15, versus the consensus of $5.94.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
Amgen, Inc. sees FY2012 EPS of $5.90-$6.15, versus the consensus of $5.94.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- BMO Capital Reiterates Outperform Rating on NVIDIA (NVDA)
- Pavion Expands Midwest Presence Through Acquisition of Communication Company
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
